Rivian Automotive, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Rivian Automotive, Inc. trades at $17.14 (market cap $25.71B), while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). The key difference: Rivian Automotive, Inc. is far larger — about 15.8× Recursion Pharmaceuticals Inc's market cap, and Rivian Automotive, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RIVN | RXRX | |
|---|---|---|
Market Cap | $25.71B | $1.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $6.79 |
52-Week Low | $11.64 | $2.84 |
Enterprise Value | $27.45B | $1.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Trailing returns across standard periods
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →